Jazz bets USD 56m on AbCellera's T-cell engagers for solid tumors

Jazz Pharmaceuticals (Nasdaq: JAZZ) has committed USD 56 million upfront to access AbCellera Biologics' (Nasdaq: ABCL) T-cell engaging multispecific antibody platform for gastrointestinal cancers and other solid tumors, in a deal that could reach USD 792 million per program if Jazz exercises its development options. The agreement covers two initial discovery programs, with a committed third program to begin within 12 months for an additional USD 28 million, and options for up to two further programs by mutual agreement.

Under the terms, Jazz holds an exclusive option on each program; upon exercise, it receives worldwide rights to develop and commercialize the resulting antibodies. AbCellera will be responsible for discovery activities through candidate selection, after which Jazz may opt into global development and commercialization rights. AbCellera is eligible for tiered royalties on net sales ranging from mid-single digits to low double digits per exercised program.

Deal context

Jazz is looking to add TCEs to its existing oncology portfolio. The company markets zanidatamab (Ziihera), a HER2-bispecific antibody approved by the US FDA in November 2024 for HER2-positive biliary tract cancer. That molecule was originally licensed from Zymeworks in 2022 in a deal that carried a USD 50 million upfront, a USD 325 million option exercise, and up to USD 1.76 billion in total value. The AbCellera collaboration extends Jazz's GI oncology presence into a next-generation modality.

The deal reflects continued pharmaceutical interest in T-cell engager platforms for solid tumors. Comparable transactions include AbbVie's 2025 collaboration with Xilio Therapeutics and Astellas' 2026 agreement with Vir Biotechnology, both deals focused on masked TCEs, highlighting sustained demand for the next-generation modality despite its relatively early stage in solid tumors.

The multi-program option architecture is notable. Most preclinical TCE deals are single-asset transactions. The Jazz/AbCellera structure — two immediate programs, a contractually committed third, and up to two additional by agreement — more closely resembles a portfolio collaboration than a standard asset license. This is structurally unusual at the preclinical stage, where program failure rates are high, and suggests Jazz is paying for sustained discovery access rather than any specific molecule.

---

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

---

Spot something wrong? Report an issue with this article